Serum C-peptide measurement is a cornerstone of diabetes diagnostics, offering a direct and quantitative window into the pancreas’s ability to produce insulin. Unlike exogenous insulin, which cannot be distinguished from endogenous insulin by standard assays, C-peptide is a unique marker that reflects the body’s own insulin secretion. This expanded review explores the role of serum C-peptide levels in confirming insulin deficiency, with a focus on clinical interpretation, diagnostic algorithms, and therapeutic implications, while also addressing limitations and emerging applications in modern endocrine practice.

The Biochemical Rationale for C-Peptide Measurement

From Proinsulin to Secretion: The Equimolar Relationship

C-peptide (connecting peptide) is a 31-amino-acid polypeptide that is cleaved from proinsulin during the maturation of insulin in the beta cells of the pancreatic islets. For every molecule of insulin secreted, one molecule of C-peptide is released into the portal circulation in equimolar amounts. This 1:1 relationship makes C-peptide an ideal surrogate for endogenous insulin secretion because its half-life in the periphery (about 30 minutes) is longer than that of insulin (4–6 minutes), providing a more stable and integrated measure of beta-cell function. Laboratories typically measure fasting C-peptide levels or stimulated levels after a mixed meal or glucagon challenge to evaluate residual beta-cell function.

Pharmacokinetic Advantages Over Insulin Measurement

Direct measurement of serum insulin is complicated by several factors. The liver extracts approximately 50-60% of insulin on first pass, creating a significant discrepancy between portal secretion and peripheral levels. Additionally, insulin antibodies from prior therapy can interfere with immunoassays. C-peptide circumvents these problems. It undergoes minimal hepatic clearance and is primarily eliminated by the kidneys, making it a more reliable surrogate for portal insulin secretion rates. This is particularly valuable in patients already on insulin therapy, where distinguishing endogenous from exogenous sources is clinically essential.

Clinical Pearl: Because C-peptide is renally cleared, levels accumulate in chronic kidney disease (CKD). An elevated C-peptide in a patient with CKD may not indicate insulin resistance; it may simply reflect reduced excretion. Always check renal function (eGFR) when interpreting C-peptide results.

Establishing the Diagnosis of Insulin Deficiency

Insulin deficiency can be absolute or relative. Absolute deficiency, characteristic of type 1 diabetes, results from autoimmune destruction of beta cells, leading to negligible endogenous insulin production. Relative deficiency occurs when insulin secretion is insufficient to meet metabolic demands, as seen in advanced type 2 diabetes or secondary diabetes. Serum C-peptide levels provide the quantitative evidence needed to distinguish these scenarios.

Defining Absolute vs. Relative Deficiency

In clinical practice, a low or undetectable C-peptide level (typically below 0.2–0.3 ng/mL in the fasting state, depending on the assay) confirms severe insulin deficiency. Such findings are highly suggestive of type 1 diabetes or long-standing type 2 diabetes with near-complete beta-cell failure. Patients with type 1 diabetes often have C-peptide levels below 0.1 nmol/L (0.3 ng/mL) after a mixed-meal stimulus, whereas healthy individuals show a clear rise. Conversely, elevated fasting C-peptide levels (above 3–4 ng/mL) often indicate insulin resistance, as the pancreas compensates by producing more insulin. This pattern is typical of early type 2 diabetes, metabolic syndrome, or conditions like acanthosis nigricans. Elevated C-peptide with concurrent hypoglycemia raises suspicion for insulinoma or sulfonylurea overdose.

Critical Interpretation of C-Peptide in Hypoglycemia

The relationship between C-peptide and glucose is critical when evaluating hypoglycemic disorders. In insulin-induced hypoglycemia (exogenous insulin administration), C-peptide is suppressed while insulin levels may be high. In insulinoma, both insulin and C-peptide are elevated during hypoglycemia. The C-peptide suppression test—where hypoglycemia is induced by insulin infusion—aids in distinguishing endogenous from exogenous hyperinsulinism. A C-peptide level above 0.2 nmol/L during hypoglycemia suggests inappropriate insulin secretion, supporting the diagnosis of insulinoma. The standard 72-hour fast remains the gold standard for diagnosing insulinoma, with C-peptide and insulin measured at the endpoint of the fast, typically when plasma glucose drops below 3.0 mmol/L (55 mg/dL) with concurrent symptoms.

Role in Differentiating Diabetes Subtypes

Differentiating type 1 from type 2 diabetes is not always straightforward, particularly in adults with latent autoimmune diabetes of the adult (LADA). C-peptide measurement, especially after a stimulated test (e.g., glucagon stimulation test or mixed-meal tolerance test), provides actionable data:

  • C-peptide < 0.2 nmol/L (0.6 ng/mL) fasting or < 0.3 nmol/L (0.9 ng/mL) stimulated: Indicates severe insulin deficiency, consistent with classic type 1 diabetes or LADA with rapid progression.
  • C-peptide 0.2–0.6 nmol/L (0.6–1.8 ng/mL) fasting: May represent residual beta-cell function in early type 1 diabetes or advanced type 2 diabetes. Further testing with autoantibodies (GAD, IA-2, ZnT8) is recommended to confirm autoimmunity.
  • C-peptide > 0.6 nmol/L (1.8 ng/mL) fasting: Suggests preserved insulin secretion, typical of type 2 diabetes or maturity-onset diabetes of the young (MODY).

The American Diabetes Association (ADA) Standards of Care in Diabetes endorse C-peptide measurement in ambiguous cases, particularly when the patient is lean, has a strong family history of diabetes, or presents with atypical ketoacidosis. In MODY, C-peptide levels are often detectable but lower than in type 2 diabetes. Genetic testing is definitive, but a stimulated C-peptide > 0.6 nmol/L (1.8 ng/mL) outside the context of obesity suggests MODY, especially when insulin sensitivity is normal.

Understanding Assay Variability and Standardization

National reference ranges for C-peptide are assay-dependent. Variability exists between chemiluminescent, ELISA, and radioimmunoassay platforms. Laboratories should provide their own reference intervals, and clinicians should ideally use the same assay for serial monitoring of a given patient. The lack of a fully standardized international reference material for C-peptide means that values from different labs may not be directly interchangeable. Clinicians should be cautious when interpreting "normal" ranges and always use the reference provided by the specific laboratory processing the sample.

Factors Affecting C-Peptide Measurement

  • Renal function: C-peptide is primarily cleared by the kidneys. In chronic kidney disease, C-peptide accumulates, leading to falsely elevated levels. Creatinine and eGFR should be assessed simultaneously. An elevated C-peptide in the context of renal failure does not reliably rule out insulin deficiency.
  • Hemolysis and sample handling: C-peptide is relatively stable, but improper storage can degrade the analyte. Samples should be centrifuged and frozen if not analyzed promptly. Hemolyzed samples can be unreliable.
  • Assay variability: Different immunoassays may yield different absolute values. Serial monitoring should use the same assay to ensure consistency.
  • Medications: Sulfonylureas and glinides stimulate endogenous insulin secretion and can increase C-peptide levels, whereas thiazolidinediones and metformin may have variable effects. Insulin therapy itself does not affect endogenous C-peptide production (unless beta-cell function has been exhausted), making it a reliable marker for residual function in insulin-treated patients.

C-Peptide Assessment in Special Populations

Pregnancy: Pregnancy is a state of progressive insulin resistance. C-peptide levels naturally rise in healthy pregnant women, particularly in the third trimester. However, gestational diabetes mellitus (GDM) is characterized by an inability to mount a sufficient compensatory insulin response. Measuring C-peptide in pregnancy can identify women with significant beta-cell dysfunction, although standard diagnostic criteria rely on oral glucose tolerance testing. In pregnant women with pre-existing diabetes, low C-peptide confirms ongoing insulin dependence.

Pediatrics: Differentiating pediatric diabetes types is critical, as misclassification can lead to inappropriate treatment. C-peptide measurement is recommended at the time of diagnosis and annually thereafter to assess residual beta-cell function. Young children with type 1 diabetes typically have very low or undetectable C-peptide levels. In adolescents with obesity and diabetes, a preserved C-peptide helps distinguish type 2 from type 1 diabetes, guiding therapy selection.

Clinical Utility: The Centers for Disease Control and Prevention (CDC) provides resources for providers on interpreting diabetes diagnostic tests, including the role of C-peptide in longitudinal care. Learn more about diabetes testing and diagnosis.

Translating C-Peptide Levels into Clinical Action

Guiding Insulin Therapy and Pump Eligibility

Patients with very low C-peptide levels (e.g., < 0.2 nmol/L) are likely to require basal-bolus insulin regimens or insulin pump therapy. Conversely, those with preserved C-peptide (> 0.3 nmol/L stimulated) may respond to non-insulin therapies such as GLP-1 receptor agonists, SGLT2 inhibitors, or sulfonylureas. The ADA recommends periodic assessment of C-peptide in people with type 2 diabetes who experience glycemic worsening, to determine if insulin therapy is needed. Furthermore, many insurance providers and health systems use C-peptide levels as eligibility criteria for continuous subcutaneous insulin infusion (CSII) pumps and continuous glucose monitoring (CGM) coverage in type 1 diabetes.

A Biomarker for Beta-Cell Preservation Therapies

In type 1 diabetes, residual C-peptide secretion is associated with lower rates of hypoglycemia and better glycemic control. Clinical trials, such as the Diabetes Control and Complications Trial (DCCT), have shown that even small amounts of endogenous C-peptide (≥ 0.2 nmol/L stimulated) reduce the risk of severe hypoglycemia by 50% and slow the progression of microvascular complications. Thus, C-peptide serves as a surrogate endpoint in intervention studies aimed at preserving beta-cell function, including immunotherapy and stem cell therapies. The ability to detect even trace amounts of C-peptide using modern ultrasensitive assays has made it possible to identify a more subtle protective effect of these emerging therapies.

Prognostic Implications for Diabetic Complications

Emerging evidence suggests that C-peptide may have direct physiological effects, including activation of the Na⁺/K⁺-ATPase pump, stimulation of endothelial nitric oxide synthase, and anti-inflammatory properties. While its primary role is diagnostic, the relationship between C-peptide and microvascular complications is complex. In type 1 diabetes, preservation of C-peptide is consistently linked to reduced rates of retinopathy and nephropathy. In type 2 diabetes, the relationship is J-shaped: very low C-peptide (indicating beta-cell failure) is associated with higher complication rates, while extremely high levels (indicating severe insulin resistance) carry their own risk. For a deeper dive into current research on C-peptide's multifaceted roles, refer to this comprehensive review on C-peptide biology.

Limitations and Practical Considerations

While C-peptide is a robust biomarker, several caveats require attention:

  • Islet autoimmunity: Low C-peptide alone does not prove type 1 diabetes; autoantibody testing is necessary to differentiate from other causes of beta-cell destruction (e.g., cystic fibrosis–related diabetes, pancreatitis, post-pancreatectomy).
  • Non-diabetic hypoglycemia: In patients with insulinoma, C-peptide levels may overlap with normal values during euglycemia. Provocative testing (fasting test, glucagon stimulation) is often needed to distinguish tumor from normal physiology.
  • Insulin resistance states: In obesity or polycystic ovary syndrome, C-peptide may be elevated due to compensatory hyperinsulinemia, masking insulin deficiency. A normal C-peptide in an obese patient may still represent relative deficiency if insulin resistance is severe.
  • C-peptide as a therapy? Despite early reports of potential renoprotective and neuroprotective effects, synthetic C-peptide is not currently approved for clinical use due to conflicting trial results.

Clinicians must integrate C-peptide results with other clinical data, including glucose levels, autoantibodies, and the patient's age, BMI, and duration of diabetes. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provides a comprehensive overview of diabetes management strategies that incorporate C-peptide testing in clinical practice.

Future Directions and Emerging Applications

Recent studies have explored the prognostic value of C-peptide in COVID-19 patients with diabetes, suggesting that low C-peptide may predict worse outcomes. Additionally, advances in ultrasensitive assays (e.g., electrochemiluminescence) now allow detection of very low C-peptide levels, enabling earlier identification of beta-cell decline in "cure" studies for type 1 diabetes. The field of "C-peptide biology" continues to expand, with investigations into its role in diabetic neuropathy, nephropathy, and endothelial function. Researchers are also exploring whether C-peptide can serve as a biomarker for the risk of hypoglycemia and for predicting the success of beta-cell replacement therapies like islet transplantation. The Endocrine Society's clinical practice guidelines on hypoglycemia and diabetes technology continue to underscore the utility of this humble but powerful marker.

Conclusion

Serum C-peptide measurement is an indispensable tool for confirming insulin deficiency, classifying diabetes type, and guiding therapy. Its ability to differentiate absolute from relative insulin deficiency, coupled with its utility in hypoglycemia workup and beta-cell monitoring, makes it a mainstay of endocrine practice. Clinicians should be aware of the limitations—especially renal function and assay variability—and always interpret levels in the context of glucose and clinical presentation. As research uncovers new functions of C-peptide and as new therapeutic strategies aim to preserve beta-cell function, the role of C-peptide in personalized diabetes care will likely grow even further, solidifying its place as a key biomarker in the fight against diabetes.